Movement, cognition and perception arise from the collective activity of neurons within
cortical circuits and across large-scale systems of the brain. While the causes of single …

Schizophrenia has been primarily associated with dopamine dysfunction, and treatments
have been developed that target the dopamine pathway in the central nervous system …

Following the discovery of the antidepressant properties of ketamine, there has been a
recent resurgence in the interest in this NMDA receptor antagonist. Although detailed animal …

The history of ketamine and phencyclidine from their development as potential clinical
anaesthetics through drugs of abuse and animal models of schizophrenia to potential …

Background: Ketamine, the NMDA glutamate receptor antagonist drug, is increasingly
employed as an experimental model of psychosis in healthy volunteers. At subanesthetic …

N-methyl-d-aspartate (NMDA) receptor antagonists administered to healthy humans results
in schizophrenia-like symptoms, which preclinical research suggests are due to …

In this article, we review (1) the importance of information integration in consciousness,(2)
early studies of network breakdown during anesthesia,(3) preclinical research …

Seizures are a prominent feature in N-Methyl-D-Aspartate receptor antibody (NMDAR
antibody) encephalitis, a distinct neuro-immunological disorder in which specific human …

Over the last two decades, the discovery of ketamine's antidepressant properties has
galvanized research into the neurobiology of treatment-resistant depression. Nevertheless …

For the past decade, ketamine, an N-methyl-D-aspartate receptor (NMDAr) antagonist, has
been considered a promising treatment for major depressive disorder (MDD). Unlike the …